Fig. 1

Flow chart patient recruitment. In this study 956 patients were observed. Patients who meet the criteria of the ICHD-3 classification for migraine were included (n = 149). For further analysis, we excluded the patients who did not meet the study requirements of at least 3 consecutive monthly injections of erenumab over ≥3 months of follow-up (n = 58). The final cohort included 91 patients